GZL626, a Novel Molecular Glue Degrader for Androgen Receptor (AR/AR-V7), Overcomes Resistance in Advanced Prostate Cancer

July 19, 2026

bioRxiv Unknown

Overview

A preprint on bioRxiv describes the identification of GZL626, a novel small-molecule molecular glue degrader that induces proteasome-dependent degradation of both full-length androgen receptor (AR) and its splice variant AR-V7. GZL626 acts by binding to the AR N-terminal domain and promoting the formation of a noncanonical RNF213–UBE2J2-AR ternary complex. This discovery offers a new therapeutic approach to overcome endocrine therapy resistance in advanced prostate cancer.

In Depth

Key Findings

In a recent preprint published on bioRxiv, researchers reported the successful identification of GZL626, a novel small-molecule molecular glue degrader with the potential to overcome endocrine therapy resistance in advanced prostate cancer. GZL626 was demonstrated to induce proteasome-dependent degradation of both the full-length androgen receptor (AR) and its splice variant AR-V7, a major driver of treatment resistance.

Technical & Clinical Details

GZL626 functions by specifically binding to the N-terminal domain (NTD) of AR, promoting the formation of a noncanonical ternary complex between AR, the intracellular ubiquitin E3 ligase RNF213, and the E2 ubiquitin-conjugating enzyme UBE2J2. This unique interaction leads to the ubiquitination of AR and AR-V7, followed by their subsequent degradation by the cellular proteasome. Unlike traditional AR inhibitors or antagonists, GZL626 works by removing the AR protein itself from the cell, thereby circumventing resistance mechanisms that often emerge with inhibitor-based therapies. In both in vitro and in vivo models, GZL626 exhibited potent anti-tumor activity in prostate cancer cell lines and tumor models that had developed resistance to existing AR-targeted therapies.

Background & Context

Hormone therapy (androgen deprivation therapy) is the cornerstone treatment for advanced prostate cancer, but many patients eventually acquire resistance and progress to castration-resistant prostate cancer (CRPC). AR splice variants, such as AR-V7, enable androgen-independent proliferation and are recognized as key mechanisms of resistance to existing AR-targeted therapies. Consequently, there has been an urgent need for new therapeutic strategies capable of effectively degrading the entire AR protein, including AR-V7. Molecular glue degraders like GZL626 are gaining attention as promising modalities to address this unmet medical need.

Strategic Significance & Outlook

The discovery of GZL626 holds the potential to revolutionize treatment for advanced prostate cancer, particularly for endocrine-resistant CRPC. Its ability to effectively degrade AR-V7 offers a new therapeutic avenue for patients who have exhausted existing drug options. If further preclinical development and subsequent clinical trials demonstrating safety and efficacy are successful, GZL626 could become a groundbreaking drug that significantly alters the prostate cancer treatment landscape. Furthermore, this research expands the design principles and applicability of molecular glue degraders, accelerating the development of targeted protein degradation drugs for other intractable cancers and diseases.

Source: https://www.biorxiv.org/content/10.64898/2026.07.14.738453v1

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.